Figure 1.

Deregulated Myc Cooperates Oncogenically with KRas^G12D in Lung

(A) Representative H&E staining of lung sections 18 weeks after activation of KRas^G12D either without (control) or with (tamoxifen) Myc deregulation for the final 6 weeks. Dotted lines in top panels highlight “inflamed” regions. Boxed regions in the top row images are enlarged in the second row of panels, and boxed regions in the middle panels are further enlarged in the bottom row. T = tumor. Black arrows indicate palisades of migratory tumor cells. Scale bars are representative for rows of panels.

(B–D) Representative immunostaining for the pan-leukocyte marker CD45 (B), the proliferation marker Ki67 (C) and the endothelial cell marker CD31 (D) of lung sections 12 weeks after activation of KRas^G12D either with (tamoxifen) or without (control) Myc deregulation for the final 6 weeks. Higher magnifications of the boxed areas are shown in the panels immediately below. T = tumor. Results shown in (C) and (D) are from serial sections. Scale bars are representative for rows of panels.

(E) Quantification analysis of Ki67 and CD31 immunostaining of lung sections 12 weeks after activation of KRas^G12D without (6 wks oil) or with (6 wks tam) Myc activated for the last 6 weeks. FoV = field of view. n = 30 individual tumors (small symbols) from 6 total mice (large symbols) per time point. Error bars represent the median with interquartile range. p values are based on Student’s t test. ^∗∗∗∗p < 0.0001.

See also Figures S1 and S2.